Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 6/20 | 0.40 |
| ▸ | F10 | P00742 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715340 | 1.00 | ESR1 (0.54) | ESR1ESR2ALDH1A1F2F10 | |
| SCHEMBL13715201 | 1.00 | ESR1 (0.54) | ESR1ESR2ALDH1A1F2F10 | |
| SCHEMBL3873610 | 0.91 | ESR1 (0.44) | ESR1ESR2ALDH1A1F2F10 | |
| SCHEMBL3874428 | 0.91 | ESR1 (0.44) | ESR1ESR2ALDH1A1F2F10 | |
| SCHEMBL3873609 | 0.91 | ESR1 (0.44) | ESR1ESR2ALDH1A1F2F10 | |
| SCHEMBL13743801 | 0.87 | ESR1 (0.51) | ESR1ESR2ALDH1A1MAPTRAB9A | |
| SCHEMBL10285065 | 0.87 | ESR1 (0.51) | ESR1ESR2ALDH1A1MAPTRAB9A | |
| SCHEMBL27323723 | 0.85 | ALDH1A1 (0.55) | ALDH1A1F2F10MAPTPRSS1 | |
| SCHEMBL2495278 | 0.82 | F10 (0.50) | ALDH1A1F2F10RAB9APRSS1 | |
| SCHEMBL27830823 | 0.82 | F10 (0.50) | ALDH1A1F2F10RAB9APRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108017603-B | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2021-07-23 | — | — | CN | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2963027-B1 | TRICYCLIC COMPOUND AND USE THEREOF | TIUMBIO CO LTD (KR) | 2018-12-26 | — | — | EP | disclosed |
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| CN-103228622-B | The agonist of GPR40 | CONNEXIOS LIFE SCIENCES Pvt.,Ltd. (IN) | 2016-01-20 | — | — | CN | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| EP-2963027-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK Chemicals Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| CN-103228622-A | Agonists of gpr40 | CONNEXIOS LIFE SCIENCES PVT LTD | 2013-07-31 | — | — | CN | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | ESR1 231/4885ESR2 183/4885ALDH1A1 2410/4885 |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | ESR1 356/4885ESR2 752/4885ALDH1A1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.